Malaria is still a public health problem in Ogan Komering Ulu (OKU) Regency. The treatment of malaria for Plasmodium falciparum in the OKU regency has been using artesdiaquine since 2007 and for Plasmodium vivax in 2009. The purpose of this study was to assess the effectiveness Artesdiaquine as anti-malarial drugs and the side effects of therapeutic. This research was conducted using an observational surveys, in P falciparum and P. vivax patient, by examination and observation of subjects during 28 days, in 0 day (DO), first day (Dl), 2nd (D2), 3th (D3), 7th (D7), 14th (DI4), 21th (D21) and 28th day (D28). Theraphy of Artesdiaquine on DO, Dl and D2 (10 mg/kg amodiaquine and 4 mg/kg artesunate), while primaquine on DO (0.75 mg/kg) for P falciparum patient and DO-DI4 (0.25 mg/kg) for P.vivax patient. The side effects observed on DO, Dl , D2 and D3, while the assessment of drug efficacy after D28. The results showed that efficacy of Artesdiaquine-antimalarial drugs combinations for P.vivax patients has good (100%), but in P falciparum patients only 87% with criteria of Adequate Clinical and Parasitological Response (A CPR). Plasmodium falciparum patient with early treatment failure (ETF) were found in 3 people (13%). The side effects of artesdiaquine were dizziness, nausea, vomiting and stomach. Patients P falciparum who did not experience medication side effects as many as 5 of 23 patients (21.7%). While in P.vivax patients were 2 of 12 patients (16.7%). Clinical symptom in P. vivax patients higher than P falciparum patients. Artesdiaquine more effective to treatment P. vivax than P falciparum patients. Side effect of treatment anti malarial higher in P falciparum than P. vivax patients.